Journal article
Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis
Critical reviews in oncology/hematology, Vol.175, pp.103706-103706
07/01/2022
DOI: 10.1016/j.critrevonc.2022.103706
PMID: 35537621
Abstract
To assess comparative effectiveness of adjuvant therapies for renal cell carcinoma and quantify the absolute benefit of adjuvant treatments by clinicopathological risk groups.
This ‘living’ review was conducted using Living Interactive Evidence (LIvE) synthesis framework.
The ‘living’ results are available on an interactive website. This network meta-analysis, including six RCTs with 7525 participants, showed that pembrolizumab (rank 1) significantly improved disease-free survival and overall survival compared with sunitinib but not when compared to pazopanib, and axitinib. The risk of treatment-related grade 3 or higher adverse events was increased with pembrolizumab as compared to placebo and axitinib but not when compared to sunitinib. The absolute benefit of adjuvant pembrolizumab increases substantially with larger tumor size, nodal positivity and higher Leibovich scores.
Current evidence suggests that pembrolizumab delays disease progression compared to sunitinib. A risk-adapted strategy should be used in patients undergoing consideration for treatment with adjuvant pembrolizumab.
•Adjuvant pembrolizumab delays disease progression compared to sunitinib in localized renal cell carcinoma.•The absolute benefit of adjuvant pembrolizumab increases with higher nuclear grade, larger tumor size, and nodal positivity.•The results of this living, interactive meta-analysis are updated on a linked website as soon as new trials are published.
Details
- Title: Subtitle
- Quantifying absolute benefit for adjuvant treatment options in renal cell carcinoma: A living interactive systematic review and network meta-analysis
- Creators
- Irbaz Bin Riaz - Mayo Clinic, Phoenix, AZ, USAQurat Ul Ain Riaz Sipra - University of ArizonaSyed Arsalan Ahmed Naqvi - Mayo Clinic HospitalHuan He - Mayo ClinicRabbia Siddiqi - Dow University of Health SciencesMahnoor Islam - Dow University of Health SciencesNoureen Asghar - University of ArizonaWaleed Ikram - Mayo Clinic HospitalWenxin Xu - Dana-Farber Cancer InstituteHongfong Liu - Mayo Clinic in ArizonaParminder Singh - Mayo Clinic HospitalThai Huu Ho - Mayo Clinic HospitalMehmet Asim Bilen - Emory UniversityYousef Zakharia - University of IowaAlan Haruo Bryce - Mayo Clinic HospitalMohammad Hassan Murad - Mayo Clinic
- Resource Type
- Journal article
- Publication Details
- Critical reviews in oncology/hematology, Vol.175, pp.103706-103706
- Publisher
- Elsevier B.V
- DOI
- 10.1016/j.critrevonc.2022.103706
- PMID
- 35537621
- ISSN
- 1040-8428
- eISSN
- 1879-0461
- Language
- English
- Date published
- 07/01/2022
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984544623102771
Metrics
5 Record Views